直线加速器8mv－x和<sup>60</sup>Co治疗鼻咽癌疗效比较

直线加速器8mv－x和⁶⁰Co治疗鼻咽癌疗效比较

摘要: 1987年至1989年采用前瞻性随机研究治疗鼻咽癌217例。分为二组，直线加速器（8mv－x）组107例，⁶⁰Co组110例，两组年龄、性别、临床分期、治疗方法、时间剂量等因素基本相同。全组5年随访率为90%，3、5年生存率分别为60.8%和43.8%，8mv－x组分别为67.3%和49.5%，⁶⁰Co组为54.5%和38.2%，8mv－x组较⁶⁰Co组稍好，但无统计学差异（P>0.05）.疗终颈部淋巴结残存率和原发灶复发率8mv－x组为25.6%和11.2%。⁶⁰Co组为34.9%和12.7%（P>0.05）。

Abstract: A prospective randomized trial in 217 nasopharyngeal carcinoma patients wasconducted from 1987 to 1989.The patients were randomized into two groups:107patients treated by linear-accelerator(8 MV-X),110 patients treated by telecobalt(60Co).The two groups were similar with srespect of The ages, sexes, clinicalstages, irradiation fiels, dosetime, factors, ect. The 5-year follow-up rate in overallgroup was 90 %. The 3, 5-years survival rates were 60. 8 % and 43. 8%, respectively.The 3, 5-years survival rates in the 8 MV-X group were 67. 3% and 49. 5%, in the60Co group were 54. 5% and 38. 2%,respectively.There was no nstatistically significant difference between the survival rates of the two groups(P0. 05).The remainof cervical lymph nodes at the end of irradiation and locol recurrence of 5-year rateswere 25. 6% and 11. 2% in the 8MV-X group, 34. 9% and 12. 7%in the 60Co group(P0. 05).